You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 24, 2024

~ Buy the PREVYMIS (letermovir) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR PREVYMIS


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Prevymis

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03728426 ↗ Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection Recruiting Merck Sharp & Dohme Corp. Phase 2 2019-01-11 The trial will evaluate the safety and efficacy of letermovir antiviral treatment of active cytomegalovirus infection or cytomegalovirus disease in patients with infections that are refractory or resistant to available treatments or who are experiencing organ dysfunction that makes unsafe the use of available antiviral treatments.
NCT03728426 ↗ Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection Recruiting Amy C. Sherman, MD Phase 2 2019-01-11 The trial will evaluate the safety and efficacy of letermovir antiviral treatment of active cytomegalovirus infection or cytomegalovirus disease in patients with infections that are refractory or resistant to available treatments or who are experiencing organ dysfunction that makes unsafe the use of available antiviral treatments.
NCT03728426 ↗ Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection Recruiting Dana-Farber Cancer Institute Phase 2 2019-01-11 The trial will evaluate the safety and efficacy of letermovir antiviral treatment of active cytomegalovirus infection or cytomegalovirus disease in patients with infections that are refractory or resistant to available treatments or who are experiencing organ dysfunction that makes unsafe the use of available antiviral treatments.
NCT04060277 ↗ Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation Recruiting National Cancer Institute (NCI) Phase 2 2019-10-07 This phase II trial studies how well Triplex vaccine works in preventing cytomegalovirus (CMV) infection in patients undergoing a hematopoietic stem cell transplantation. CMV is a virus that may be carried for life and does not cause illness in most healthy individuals. However, in people whose immune systems are lowered (such as those undergoing stem cell transplantation), CMV can reproduce and cause disease and even death. The Triplex vaccine is made up of 3 small pieces of CMV deoxyribonucleic acid (DNA) (the chemical form of genes) placed into a weakened virus called modified vaccinia Ankara (MVA) that may help produce immunity (the ability to recognize and respond to an infection) and reduce the risk of developing complications related to CMV infection.
NCT04060277 ↗ Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation Recruiting City of Hope Medical Center Phase 2 2019-10-07 This phase II trial studies how well Triplex vaccine works in preventing cytomegalovirus (CMV) infection in patients undergoing a hematopoietic stem cell transplantation. CMV is a virus that may be carried for life and does not cause illness in most healthy individuals. However, in people whose immune systems are lowered (such as those undergoing stem cell transplantation), CMV can reproduce and cause disease and even death. The Triplex vaccine is made up of 3 small pieces of CMV deoxyribonucleic acid (DNA) (the chemical form of genes) placed into a weakened virus called modified vaccinia Ankara (MVA) that may help produce immunity (the ability to recognize and respond to an infection) and reduce the risk of developing complications related to CMV infection.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Prevymis

Condition Name

Condition Name for Prevymis
Intervention Trials
Hematopoietic and Lymphoid Cell Neoplasm 2
Chronic Lymphocytic Leukemia 2
Lymphadenopathy 1
T-Cell Prolymphocytic Leukemia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Prevymis
Intervention Trials
Lymphoma 2
Leukemia, Lymphocytic, Chronic, B-Cell 2
Neoplasms 2
Leukemia 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Prevymis

Trials by Country

Trials by Country for Prevymis
Location Trials
United States 5
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Prevymis
Location Trials
California 2
Pennsylvania 1
Ohio 1
Massachusetts 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Prevymis

Clinical Trial Phase

Clinical Trial Phase for Prevymis
Clinical Trial Phase Trials
Phase 3 1
Phase 2 5
N/A 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Prevymis
Clinical Trial Phase Trials
Not yet recruiting 4
Recruiting 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Prevymis

Sponsor Name

Sponsor Name for Prevymis
Sponsor Trials
Merck Sharp & Dohme Corp. 4
National Cancer Institute (NCI) 2
Ohio State University Comprehensive Cancer Center 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Prevymis
Sponsor Trials
Other 7
Industry 4
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.